CTLA4 and cancer: Immune checkpoint inhibitors (ICIs) are novel antineoplastic therapies that revolutionized treatment of cancer in 2011 after the approval of anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4), ipilimumab, for the treatment of melanoma [1].